Periodic restriction of animal products rapidly decreases cardiovascular disease risk and reduces low-grade inflammation: the FastBio study

Eleni M. Loizidou[1,2], Alexandros Simistiras[1], Petros Barmpounakis[3], Stavros Glentis[1,4], Alexandros Dimopoulos[1,5], Maria Anezaki[1], Anargyros Skoulakis[1], Ioannis Kontoyiannis[6], Nikolaos Demiris[3], Pavlos Rouskas[7], Nikolaos Scarmeas[8,9], Mary Yannakoulia[10], Konstantinos Rouskas[1,11], Antigone S. Dimas[1*]

[1] Institute for Bioinnovation, Biomedical Sciences Research Center 'Alexander Fleming', Fleming 34, 16672, Vari, Greece

[2] biobank.cy Center of Excellence in Biobanking and Biomedical Research, University of Cyprus, Cyprus

[3] Department of Statistics, Athens University of Economics and Business, Athens, Greece

[4] Pediatric Hematology/Oncology Unit (POHemU), First Department of Pediatrics, University of Athens, Aghia Sophia Children's Hospital, Levadias 8, 11527, Athens, Greece

[5] Hellenic Naval Academy, Hatzikyriakou Avenue, Piraeus 185 39, Greece

[6] Statistical Laboratory, Centre for Mathematical Sciences, University of Cambridge, United Kingdom

[7] 1st Department of Cardiology, AHEPA University Hospital, Aristotle University, Thessaloniki, Greece

[8] Department of Neurology, Columbia University, New York, NY, USA

[9] 1st Department of Neurology, Medical School, National and Kapodistrian University of Athens

[10] Department of Nutrition and Dietetics, Harokopio University, Athens, Greece

[11] Institute of Applied Biosciences, Centre for Research & Technology Hellas, Thessaloniki, Greece

Corresponding author:

Email address: dimas@fleming.gr

Institute for Bioinnovation, Biomedical Sciences Research Center 'Alexander Fleming', Fleming 34, 16672, Vari, Greece

Full word count: 4,579

Lay summary

We sought to discover the impact of periodic restriction of animal products on human health and explore its effects on blood biomarkers. Three to four weeks of restriction was associated with:

- A reduction in levels of total and LDL cholesterol and a concurrent reduction in the 10-year risk for CVD
- A reduction in levels of low-grade inflammation and lower white blood cell counts

ABSTRACT

Aims: Dietary interventions constitute a means of untapped potential for the prevention and management of diseases including cardiovascular disease (CVD) and inflammatory disorders. The extent to which dietary modification can contribute to disease prevention and treatment however remains unclear. Toward this end, we addressed the effects of a dietary pattern involving periodic restriction of animal products on markers of health.

Methods: We profiled a unique group of 200 individuals who alternate between omnivory and animal product restriction for religious reasons. Periodically restricted (PR) individuals practice restriction for 180-200 days annually, in a consistent and temporally structured manner. We also profiled 211 continuously omnivorous, non-restricted (NR) individuals for comparison purposes. Traits were measured during a period of omnivory for both groups, and during a period when PR individuals had undergone restriction for three to four weeks. We used linear mixed effects models to report changes in blood biomarkers, complete blood counts, anthropometric traits and blood pressure.

Results: Restriction was linked to a reduction in levels of: total and LDL cholesterol [both β=-0.3, p<0.0001], CRP [β=-1.3, p=0.001] which decreased by 72.8%, platelet counts [β=-9.8, p<0.0001] and a concurrent reduction in CVD risk (5.3% to 4.9%, p=0.02) shifting PR individuals from a high to a low-to-moderate risk group. Beneficial changes were recorded for markers of renal and liver function, with the exception of ALP [β=2.5, p<0.0001].

Conclusions: Short-term animal product restriction drives mostly beneficial effects on markers of health, including a reduction of CVD risk, suggesting that modest dietary modifications can be harnessed towards disease prevention.

Keywords: CVD prevention, inflammation, biomarkers, dietary pattern

Introduction

Dietary patterns that partially or wholly exclude animal products have been associated with a low risk of major chronic diseases, including cardiovascular disease, type 2 diabetes and inflammatory bowel disease [1-3]. Indeed, there is growing evidence that plant-based diets have the potential to act as powerful interventions for the prevention and treatment of a wide range of conditions [4] with cross-sectional and interventional studies linking them to beneficial effects on BMI, total and LDL cholesterol, blood glucose, CRP, serum urea, urinary creatinine and γ-GT [3, 5-10]. Vegan diets in particular, which involve complete abstinence from all animal products, have been additionally associated with lower risk of cancer incidence, diabetes, diverticular disease, cataracts [3, 9, 10], but to a higher risk of bone fractures [9-11]. Emerging evidence also suggests an impact on the immune system [12, 13] with vegan diets also being linked to improvement of symptoms in rheumatoid arthritis patients [14]. Despite their beneficial effects however, these diets can be restrictive, thus, individuals often choose to abstain from some animal products or to only reduce meat consumption. Consequently, there is a growing trend toward flexitarian approaches (flexible diets involving the consumption of a range of plant-based foods with limited animal product consumption) which have been linked to health benefits including diabetes risk and blood pressure reduction [15]. This dietary shift is also recommended by the European Society of Cardiology (ESC) with its latest guidelines recommending the substitution of meat with plant foods for the improvement of cardiovascular health [16].

Given the substantial beneficial effects of dietary patterns that restrict animal products, it is important to gain a comprehensive understanding of how they impact markers of human health. To date, most studies involving large numbers of individuals are cross-sectional and while they build on existing knowledge, they do not allow for causal inference and usually report on a relatively limited number of outcomes or measurements. Important insight has been provided by meta-analyses of observational studies and randomised controlled trials (RCTs), but these studies suffer from limitations arising from the heterogeneity of primary studies analysed. Heterogeneity pertains to the variability in dietary patterns (e.g. vegan, vegetarian, flexitarian), to the health status of participants (e.g. healthy, obese, at-risk, patients), to the dietary intake of control groups (e.g. no dietary intervention, specific dietary interventions), to lack of adjustment for important confounders (e.g. sex, age, and BMI) and to the duration of the dietary intervention (a few weeks to several months). Typically, most studies involve interventions of over 12 weeks and thus do not map acute responses to dietary interventions, although there are some studies involving shorter interventions [12].

To address the gaps in our knowledge, we established FastBio (Fasting Biology), a comprehensive study focusing on a unique subgroup of the Greek population that follows a lifelong dietary pattern involving periodic restriction of animal products [17]. These individuals alternate between omnivory and restriction, for religious reasons, in a temporally structured manner. We explore effects of this dietary pattern on markers of health and compare findings to those from a continuously omnivorous group from the general population.

Methods

Recruitment and selection of participants

The FastBio study was advertised during Autumn 2017 to the local communities of Thessaloniki, Greece through various means, including the press, radio, social media, and word of mouth. Candidate participants expressed their interest via telephone, email or via the project's website (www.fastbio.gr). Following screening of over 1,000 candidates through two interviews, 411 apparently healthy, unrelated individuals, who met FastBio selection criteria (Supplementary Text S1) were included in the study. Participants belonged to one of two groups, specified by their dietary habits: 200 individuals who follow a temporally structured dietary pattern of periodic restriction of animal products (periodically restricted, PR group) and 211 individuals who follow the diet of the general population (non-restricted group, NR group). PR individuals constitute a unique study group given their consistent and predictable adherence to a specific dietary pattern (Supplementary Text S2). Restriction is practiced for religious reasons, as specified by the Greek Orthodox Church and involves alternating between omnivory and restriction of animal products, including meat, fish, dairy products and eggs (but not molluscs and shellfish), for 180-200 days annually. This dietary pattern is temporally structured with a specific periodicity involving four extended periods of restriction throughout the year, as well as restriction on Wednesdays and Fridays of each week (Supplementary Fig. S1). During periods of restriction, PR individuals also typically consume less alcohol. When not restricted, PR individuals follow an omnivorous type of diet. Only PR individuals who had practised periodic restriction of animal products for at least ten years were included in the FastBio study. Notably, very few participants were receiving dietary supplements (Supplementary Text S3). NR participants were omnivorous individuals from the general population, who were not under any kind of special diet.

Collection of data, of biological material and measurement of traits

FastBio participants were invited to two scheduled appointments at the Interbalkan Hospital of Thessaloniki. The first appointment took place in October-November 2017 (Timepoint 1, T1)

and covered a period where all PR individuals had been on an omnivorous diet (excluding Wednesdays and Fridays) for a period of eight or nine weeks. The second appointment (Timepoint 2, T2) took place in March 2018, and covered a period during which PR individuals had abstained from meat, fish, dairy products and eggs for three to four weeks during the abstinence period prior to Easter (Lent). At T2, a recall rate of 95% was achieved, with 192 (out of 200) PR participants and 198 (out of 211) NR participants attending both appointments. All appointments were scheduled between 7:30-9:30 am to minimize circadian effects and were completed during a two-week window to minimize effects of seasonality [18]. The ethics committee of BSRC Alexander Fleming approved the study protocols, the study was performed in line with the principles of the Declaration of Helsinki, and all participants provided written informed consent.

For each participant, following overnight fasting, a blood sample was collected by a certified nurse and was taken for biomarker and complete blood count (CBC) testing at the InterBalkan Hospital facilities (cobas c 311 analyzer, Roche Diagnostics) and for gDNA extraction at BSRC Alexander Fleming. We report results on 16 blood (serum) biomarker traits and 23 CBC traits (Supplementary Table S1). Biomarkers were grouped to allow for broad interpretation [5]: blood lipids (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides), glucose metabolism (glucose, insulin, HbA1c), renal function (urea, uric acid, creatinine), liver function (aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (γ-GT)), bone and liver function (alkaline phosphatase (ALP)), thyroid function (thyroid-stimulating hormone (TSH)), and inflammation (C-reactive protein (CRP)). Using glucose and insulin measurements, we calculated homeostatic model assessment (HOMA) indices to assess beta-cell function (HOMA-B) and insulin resistance (HOMA-IR) (Supplementary Text S4). Height was measured to the nearest 0.5 cm using a stadiometer. Body weight was measured with the use of a calibrated digital scale with an accuracy of ±100g. BMI was calculated as body weight divided by the square of height (kg/m^2). Systolic and diastolic blood pressure (SBP and DBP respectively) were measured using a traditional sphygmomanometer.

gDNA was isolated from blood using the PureLink™ Genomic DNA Mini Kit (Invitrogen, LifeTech, USA) and genotyping was on the Illumina GSA-24v3-0 array (5200 Illumina Way, San Diego, CA 92122) on 654.027 single nucleotide polymorphisms (SNPs). Upon standard QC [19] we excluded three first degree relatives and a single sample with call rate < 98%. Samples were filtered for genotype success rate > 98%. We performed principal component analysis using PLINK [20] on autosomal SNPs and plotted the first two eigen vectors and did not detect outliers. We imputed autosomal variants to ~5.1 million SNPs (minor allele frequency (MAF)

≥5%, info score ≥ 0.8 and Hardy-Weinberg Equilibrium (HWE) p-value ≥ $1e − 7$) for 407 participants for downstream analysis.

Statistical analysis

Multivariable regression analysis using linear mixed effects (lme) models with random effects ("nlme" R version 4.1.1) was performed. The sampling distribution for each trait was investigated and eight non-normally distributed traits (triglycerides, glucose, insulin, creatinine, AST, ALT, γ-GT and CRP) were log-transformed prior to regression analyses. For CRP, we excluded 49 individuals (25 PR and 24 NR) with values suggesting acute inflammation (CRP>5 mg/L). We report within-group changes in measured traits between T1 and T2, with T2 (restriction timepoint) as the reference timepoint (Supplementary Text S5). Between-group differences within each timepoint are also reported with PR as the reference group (Supplementary Text S5). Tukey's correction was performed for all associations and *P*-values < 0.05 were considered statistically significant.

Blood biomarkers and CBC traits

We fitted lme models on measured traits with sex, age, and BMI as fixed confounders (Supplementary Text S6, Table S2) and included an interaction term between dietary group (PR or NR) and timepoint (T1 or T2) to conduct comparisons. We also corrected for medication use to account for effects on measured traits (Supplementary Text S7). Adjusting for smoking and alcohol consumption did not have an impact on our results (Supplementary Text S7). Individual heterogeneity was accounted for by including participant ID as a random intercept.

Anthropometric traits and blood pressure

We fitted lme models on weight and BMI as described in Section 2.3.1., but without adjustment for BMI. We also fitted lme models for SBP and DBP with the above covariates, adjusting additionally for smoking status, which is a known risk factor for hypertension [21]. Participants were defined as smokers and non-smokers (with past smokers and e-cigarette users also considered as non-smokers) based on NHS guidelines (https://www.nhs.uk/live-well/quit-smoking/using-e-cigarettes-to-stop-smoking/).

Sensitivity analysis on LDL levels with adjustment for genetic effects

Given the impact of genetic variants on blood lipid levels [22] we conducted a sensitivity analysis on LDL cholesterol levels using the model structure described in Section 2.3.1, but with an additional adjustment for genetic effects. We calculated a polygenic risk score (PRS) based on a 165-SNP score developed by Vanhoye et. al [23]. After merging the 165-SNP panel with our variants, we retrieved 124 SNPs along with their corresponding weights and harmonized

risk alleles [24] to ensure consistency in direction of SNP effects. The PRS was calculated for each participant as the sum of the dosage effect of the risk allele of each SNP multiplied by its corresponding weight.

Calculation of 10-year CVD risk score

The 10-year CVD risk score was calculated for participants ≥ 40 years old, as specified by the ESC guidelines, through the SCORE2 risk calculators (https://u-prevent.com/calculators/ascvdScore). ESC defines four risk groups based on country-specific CVD mortality, with Greece belonging to the moderate risk group, therefore the moderate risk calculator was used [25]. The SCORE2 and SCORE2-OP algorithms were applied to individuals aged 40-69 years old and ≥ 70 years old respectively. The scores take into account age, sex, smoking status, SBP, total cholesterol and HDL cholesterol as predictors and are applicable to apparently healthy individuals with no previous CVD or type 2 diabetes mellitus. We calculated the score for 158 PR individuals (89 females and 69 males) and 122 NR individuals (65 females, 57 males) for both timepoints. A Wilcoxon signed-rank test was used to assess the change (%) in the CVD risk score across timepoints and a *P*-value < 0.05 was considered statistically significant.

All statistical analyses were performed using R software, version 4.1.1.

Results

Study population characteristics

Table 1 and Supplementary Table S2 show the baseline characteristics of FastBio participants. Compared to NR individuals, PR were on average older, had higher BMI and blood pressure and were less likely to smoke (Table 1). Both groups consisted of slightly more female participants while most individuals were non-smokers (never smoked or stopped). The vast majority were apparently healthy (according to self-reports) although a minority had underlying chronic conditions, including diabetes, arterial hypertension and hypothyroidism, for which treatment was being received (Supplementary Table S3). Mean values of blood biomarkers and CBC traits at both timepoints are summarised in Supplementary Table S1.

Within-group changes in measured traits between T1 and T2

Blood biomarkers

In the PR group, we report changes in 9 out of the 16 blood biomarkers measured (Table 2, Fig. 1) including notable reductions in total and LDL cholesterol, urea, creatinine, ALT, and γ-GT.

Furthermore, we report a remarkable decrease in levels of CRP (72.8%, p = 0.001). A small decrease is also reported in levels of HDL cholesterol. An increase was only observed in levels of ALP (Table 2). In NR individuals we report only small changes in levels of creatinine and γ-GT (Table 2, Fig. 1). The sensitivity analysis performed for LDL cholesterol using a PRS-adjusted model showed no genetic effect on LDL cholesterol levels for either of the dietary groups (PR: β = -0.3 mmol/L, p < 0.0001 and NR: β = 0.04 mmol/L, p = 0.4).

CBC traits

We report changes in 13 and 10 out of the 23 CBC traits measured, in the PR and NR groups respectively (Table 3, Fig.1) with both dietary groups displaying a reduction in total white blood (WBC) counts. Furthermore, both groups, display changes in lymphocyte %, monocyte %, neutrophils and neutrophil % (Table 3) while for red blood cell traits we report a decrease in MCH, MCV, and RDW SD (Table 3, Fig.1). In the PR group only, we report an increase in eosinophil %, and decreased levels of hemoglobin, haematocrit, MCHC, and platelets. In the NR group only, we report a small increase in monocytes and red blood cells (RBC) (Table 3, Fig.1).

Anthropometric traits and blood pressure

A very small decrease in BMI was observed in the PR group only, from T1 to T2. Additionally, a small decrease in DBP was observed for both dietary groups (Table 4).

Fig. 1: Changes in measured traits from T1 to T2. Three to four weeks of animal product restriction affected multiple markers of health in PR individuals (red) resulting in prominent reductions in levels of total and LDL cholesterol and of CRP. Fewer changes, most likely capturing seasonal effects on the immune system, were recorded for the NR group (blue).

Abbreviations: PR, periodically-restricted; NR, non-restricted; LDL-C, Low-Density Lipoprotein-Cholesterol; HDL-C, High- Density Lipoprotein-Cholesterol; HbA1c = Hemoglobin A1c; HOMA-B, HOMA- Beta-Cell Function; CRP, C-Reactive Protein; WBC, White Blood Cells; MCH, Mean Corpuscular Hemoglobin; RDW CV, Red Cell Distribution Width Coefficient Of Variation; RDW SD, Red Cell Distribution Width Standard Deviation; MCHC, Mean Corpuscular Hemoglobin Concentration; MCV, Mean Corpuscular Volume; P-LCR, Platelet-Large Cell Ratio; AST, Aspartate Aminotransferase; ALT, Alanine Aminotransferase; γ-GT, Glutamyltransferase; ALP, Alkaline Phosphatase.

10-year CVD risk score

Upon restriction, the CVD risk score of PR individuals (mean age = 56.0 years old) decreased from 5.3% to 4.9% (p = 0.02) resulting in a shift of PR individuals from the high to the low-to-moderate risk group according to the latest ESC guidelines [16]. No change in CVD risk score was detected for NR individuals (from 5.2% to 5.0%, p = 0.2).

Between-group differences of measured traits within T1 and T2

At T1, when both dietary groups were on an omnivorous diet, we report no differences in blood biomarker levels between PR and NR individuals (Table 2). At T2 (restriction timepoint), we report lower levels of total and LDL cholesterol, urea and creatinine for the PR group, but higher levels of ALP (Table 2). We also report differences for CBC traits with PR individuals displaying lower levels of eosinophils and eosinophil % at T1, and lower levels of WBC and neutrophils at T2 compared to the NR group (Table 3). No differences were observed in anthropometric or blood pressure traits between dietary groups.

Discussion

Principal findings

Short-term animal product restriction was linked to a substantial decrease in the levels of total and LDL cholesterol and to a lowering of CVD risk. This was accompanied by a 72.8% decrease in low-grade inflammation as measured through normal-range levels of CRP, and by improvements in markers of renal and liver function. A notable exception was ALP, a proxy of liver and bone health [26], which increased upon restriction and may reflect negative effects on bone health. Given that this flexitarian type of dietary pattern is relatively easy to implement, further work is required to evaluate its long-term effects on cardiovascular health, including its impact on liver fat accumulation [27], and its potential for lowering of risk for chronic diseases.

Blood lipids

We report rapid decreases of both total and LDL cholesterol levels upon animal product restriction. The reduction in LDL cholesterol levels was independent of genetic factors that are known to shape this trait. These reductions translated into a lower CVD risk upon restriction as measured by SCORE2 and an accompanying shift of PR individuals from a high to a low-to-moderate risk CVD category. SCORE2 [25], an index based on age, sex, smoking habits, SBP, total cholesterol and HDL cholesterol, is a widely accepted tool used by clinicians for the prediction of 10-year risk for fatal and non-fatal CVD events. Our analysis showed that CVD risk scores changed from 5.3% to 4.9% for the PR group and from 5.2% to 5.0% for the NR

group. Despite being only of slightly higher magnitude, the change in the risk score was only significant for the PR group. Notably, the PR group is on average older and with a higher BMI (Table 1). Considering that aging is a non-modifiable risk factor for CVD events [28] and that increasing BMI is one of the leading risk factors for CVD [29], the documented shift to the lower CVD risk category through this short term dietary intervention is of key importance.

Furthermore, while animal product restriction drove lower levels of total and LDL cholesterol, it was also linked to a slight decrease of HDL cholesterol levels. This effect on blood lipids has been reported previously [9, 30] and the usefulness of including HDL cholesterol in CVD risk prediction scores has been challenged [30]. Given the impact of dietary intake on CVD risk, incorporating dietary information in CVD prediction models, in addition to the classical CVD risk factors, could improve robustness of patient classification and of CVD risk prediction.

Despite the relatively short duration of restriction, the reduction in total and LDL cholesterol reported here (0.3 mmol/L) was larger or comparable to changes reported in meta-analyses of RCTs studying similar types of dietary interventions, including vegan diets that are three times longer in duration [6, 7]. For example, in a meta-analysis of individuals at high risk of CVD, Rees et al. report reductions of 0.24 mmol/L and 0.22 mmol/L for total and LDL cholesterol respectively, after at least 12 weeks of a vegan diet [7]. Similarly, Selinger et al [9] report a decrease of 0.48 mmol/L in LDL cholesterol in a meta-analysis of healthy individuals following a vegan diet for at least 12 weeks. Meta-analyses for similar dietary interventions in individuals with overweight, diabetes or at high risk for CVD report reductions in levels of total and LDL cholesterol ranging from 0.07 to 0.24 mmol/L [6, 9]. Through FastBio, we therefore unveil comparable effects on blood lipids with an intervention that is easy to apply and is of a shorter duration.

To put our finding in context, statin use lowers LDL cholesterol levels by an average of 1.8 mmol/L, reducing risk of ischemic heart disease (IHD) events by 60% and of stroke by 17% [31]. Although the effects reported in the present study are of lower magnitude, they are nevertheless rapid and substantial suggesting that this type of dietary pattern can be used to ameliorate CVD risk rapidly, but can also be applied in combination with lipid-lowering therapy as a preventive measure against CVD events, to amplify therapeutic effects or to modulate optimal dosing and to reduce adverse reactions.

Markers of inflammation and immune system cells

Following restriction, a 72.8% reduction was recorded for circulating, normal range levels of CRP in PR individuals, suggesting a tempering effect of this diet on levels of low-grade inflammation. Some evidence in the same direction is provided by meta-analysis of cross-

sectional studies showing that permanent vegans have lower concentrations of CRP compared to omnivorous individuals [32].

Importantly, the design of the present study enabled us to capture likely seasonal effects on the immune system. From autumn (T1) to spring (T2) both dietary groups undergo changes in total WBC counts, lymphocyte %, monocyte %, neutrophil counts and neutrophil %, in line with findings from the UKBB [18] (with the exception of monocyte %). In addition to seasonal findings, we report higher levels of eosinophil % and lower levels of hemoglobin, hematocrit, MCHC and platelets in the PR group only, effects likely driven by restriction. The decrease observed in platelets, which in addition to their role in haemostasis and thrombosis can initiate or modulate protective or adverse immune functions [33], is in line with findings from a smaller interventional study on 53 individuals who followed a four-week course of vegan diet [12]. The same study reported that numbers of monocytes and neutrophils, but not lymphocytes, decreased, with no changes reported for the dietary group following a meat-rich diet. Notably, a recent study on vegan versus ketogenic diets in humans [13] reported that neutrophils were the main driver of upregulated innate immunity following a two-week vegan diet.

Summarizing our findings on the markers of inflammation and immune system, we conclude that the reduction in CRP levels is remarkable, as translational research studies and clinical trials highlight the central role of inflammation in the development of atherosclerosis [34]. Although successful pharmacological approaches for the past 40 years were centred around LDL cholesterol lowering only, clinicians now have strong evidence that inhibition of inflammatory targets including CRP, IL-6 and IL-1β can protect against atherosclerosis [35]. An example of such a trial is CANTOS, which targeted IL-1β through an antibody resulting in reduction of major CVD events by 15-17% [35]. The inhibition of IL-1β was directly linked to the reduction in IL-6 and CRP. Therefore, elucidating the modulatory effect of dietary interventions on the immune system remains a largely untapped resource of enormous potential for the prevention and treatment of disease.

Renal, liver and bone health

Building on knowledge from cross-sectional studies [5], we report rapid reductions in levels of urea and creatinine following animal product restriction, likely reflecting a decrease in protein intake. We also observed a decrease in levels of ALT upon restriction, suggesting lower levels of fat deposition in the liver [36, 37] and potentially protective effects against hepatic steatosis [38]. Furthermore, at T2, levels of γ-GT are reduced for both PR and NR groups, likely reflecting lower levels of alcohol consumption. Although this was expected for the PR group, lower γ-GT levels in the NR group may be a consequence of awareness bias following participation in the

study at T1, and subsequent curbing of alcohol consumption. Notably, ALP levels increased upon restriction suggesting possible negative effects on bone or liver health [26]. Large cross-sectional cohort studies have shown that permanent vegans have a higher risk of bone fractures [11]. We suggest that higher ALP levels may reflect negative effects of periodic restriction of animal products on bone health, but further studies are needed to establish the magnitude of effect of this dietary pattern on bone health by using more representative tests such as quantification of bone mineral density (BMD), bone-specific ALP, C-terminal telopeptide (CTx) and parathyroid hormone [39].

Strengths and limitations

The key strength of the FastBio study is that it comprises a unique group of individuals who have followed a specific dietary pattern, in a consistent and predictable manner, for at least a decade. FastBio PR individuals therefore are highly homogeneous in the foodstuffs they abstain from, and we hypothesize that restriction from these products drives a large fraction of reported effects. Despite the enormous potential of dietary interventions to contribute to the prevention and treatment of disease, attaining this level of homogeneity in dietary studies is challenging and adhering consistently to specific diets for prolonged periods of time can prove difficult, resulting in substantial heterogeneity in the dietary groups studied. Furthermore, in contrast to studies reporting on a few measurements, FastBio is one of the most comprehensive studies addressing the effects of animal product restriction on markers of health, reporting on 16 biomarker and 23 CBC traits, as well as on anthropometric and blood pressure traits. Importantly, the FastBio study enables us to disentangle effects driven by seasonality and given the sampling strategy applied, to minimise circadian effects on traits such as WBCs and CRP that are known to display significant daily variation [18].

A limitation of the FastBio study is that traits were measured at two distinct timepoints (approximately five months apart), but not immediately prior to initiation of restriction, meaning that we do not have typical baseline measurements. Prior to initiation of restriction however, PR individuals had undergone a period of omnivory that was similar in length to the period of omnivory prior to T1. This supports the idea that prior to restriction at T2, for the traits measured in the present study, the PR group had a similar biological profile to that measured at T1. Furthermore, most blood biomarkers measured are known to capture relatively acute dietary effects, meaning that with the present measurements we are underpowered to detect likely long-term effects of periodic restriction of animal products on cardiovascular health. Another limitation of our study is that we report on low-grade inflammation through quantification of CRP levels instead of high-sensitivity CRP (hs-CRP), which is more commonly used to detect

the risk for inflammatory conditions [40]. Finally, although we have adjusted for confounding factors to the best of our ability, some residual effects may persist in reported results.

Conclusions

Over the past decades flexible dietary patterns that are compatible with food variety, cultural traditions, and personal preferences are growing in popularity [41]. The combination of these elements can be found in flexitarian type of diets that are less restrictive and have a likely positive impact on cardiovascular health[15]. The dietary pattern presented here constitutes such an approach and results in immediate beneficial effects on total and LDL cholesterol levels, CVD risk, renal and liver health, and in a tempering effect on low-grade inflammation. Although further work is necessary to address potential negative effects on bone health and to evaluate long-term effects, harnessing flexitarian type of dietary interventions is a promising approach that can be applied for disease prevention, and that can inform on future public health dietary guidelines.

Table 1. Participant characteristics at timepoint 1 (T1) [a]

	PR (N=200)	NR (N=211)	Total (N=411)
Age (years)	51.5 ± 13.5	45.0 ± 13.1	48.1±13.6
Sex (female %)	108 (54.0)	116 (55.0)	224 (54.5)
BMI (kg/m^2)	28.4 ± 4.6	26.2 ± 4.4	27.3 ± 4.6
Smoking status (Yes %)	13 (6.5)	70 (33.2)	83 (20.2)
Blood pressure (mmHg)			
SBP	127±19.0	121±19.7	124±19.4
DBP	80±10.8	78±11.8	79±11.3

[a] Continuous variables were expressed as mean ± standard deviations and categorical variables as %.
BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure

Table 2. Within-group changes in blood biomarkers from T1 to T2 and between-group differences within T1 and T2.

	PR group			NR group			Between-group estimate (T1)	Between-group estimate (T2)
Measured traits Blood biomarkers	**Within-group Estimate**	**P-value**	**95% CI**	**Within-group Estimate**	**P-value**	**95% CI**		
Total cholesterol (mmol/L)	-0.3	<0.0001***	-0.4, -0.2	0.03	0.4	-0.04, 0.1	0.04	-0.3***
LDL (mmol/L)	-0.3	<0.0001***	-0.4, -0.2	-0.04	0.3	-0.1, 0.03	-0.001	-0.3***
HDL (mmol/L)	-0.07	<0.0001***	-0.1, -0.04	-0.01	0.4	-0.04, 0.01	0.05	-8.8e-3
Triglycerides (mmol/L)	1.3e-3	0.04*†	1.03e-4, 2.6e-3	5.2e-4	0.4	-6.5e-4, 1.8e-3	-1.3e-4	4.1e-4
Glucose (mmol/L)	2e-4	0.5	-4e-4, 8e-3	6e-4	0.03*†	1e-4, 2e-3	-2.1e-4	0.001
Insulin (mU/L)	0.07	0.03*†	0.01, 0.1	0.04	0.2	-0.02, 0.1	0.008	0.04
HbA1c (%)	-0.03	0.05*†	-0.06, -5e-4	0.002	0.9	-0.03, 0.03	-0.02	0.05
Urea (mg/dL)	-5.8	<0.0001***	-6.9, -4.8	0.2	0.7	-0.8, 1.2	0.7	-4.9***
Uric acid (mg/dL)	-0.06	0.2	-0.1, 0.03	-0.02	0.6	-0.1, 0.06	0.1	-0.1
Creatinine (mg/dL)	-0.06	<0.0001***	-0.07, -0.04	-0.02	0.01*	-0.04, -0.004	-0.01	-0.05**
AST (U/L)	0.04	0.03*†	4e-3, 0.07	0.02	0.3	-0.02, 0.05	0.005	-0.03
ALT (U/L)	-0.09	0.0001***	-0.1, -0.05	-0.04	0.06	-0.09, 0.002	-0.01	-0.07
γ-GT (U/L)	-0.1	<0.0001***	-0.2, -0.1	-0.09	<0.0001***	-0.1, -0.06	-0.06	-0.1*†
ALP (U/L)	2.5	<0.0001***	1.3, 3.7	0.5	0.4	-0.6, 1.7	3.6*†	5.9**
TSH (mIU/L)	0.05	0.5	-0.08, 0.2	0.1	0.04*†	0.01, 0.3	0.3*†	-0.2
CRP (mg/L)	-1.3	0.001**	-2.1, -0.5	-0.4	0.3	-1.3,0.4	0.2	-0.6
HOMA								
HOMA-B (--)	13.3	0.02*†	2.1, 24.5	-3.8	0.5	-14.9, 7.2	-3.4	12.4
HOMA-IR (--)	0.2	0.4	-0.3, 0.7	-0.2	0.4	-0.7, 0.3	-0.5	-0.01

P-value: * ≤ 0.05, ** ≤ 0.001, *** ≤ 0.0001. Analyses adjusted for age, sex, BMI and medication use.

† = not significant after Tukey's correction

Abbreviations: *LDL = Low-Density Lipoprotein, HDL = High-Density Lipoprotein, HbA1c = Hemoglobin A1c, AST = Aspartate Aminotransferase, ALT = Alanine Aminotransferase, γ-GT = Glutamyltransferase, ALP = Alkaline Phosphatase, TSH = Thyroid-Stimulating Hormone, CRP = C-Reactive Protein, HOMA = Homeostasis Model Assessment, HOMA-B =HOMA-Beta-Cell Function, HOMA-IR = HOMA-Insulin Resistance*

Table 3. Within-group changes in CBC traits from T1 to T2 and between-group differences within T1 and T2.

Measured traits CBC	PR group			NR group			Between-group estimate (T1)	Between-group estimate (T2)
	Within-group Estimate	*P*-value	95% CI	Within-group Estimate	*P*-value	95% CI		
WBC (K/µL)	-0.4	<0.0001***	-0.6, -0.3	-0.3	0.0001***	-0.5, -0.2	-0.4*†	-0.4*
Lymphocytes (x10³/µl)	-0.04	0.1	-0.09, 0.01	-0.008	0.8	-0.06, 0.04	-0.04	-0.06
Lymphocyte % (%)	1.6	0.0004**	0.7, 2.5	1.6	0.0003**	0.8, 2.5	1.1	1.0
Eosinophils (x10³/µl)	0.0006	0.4	-0.008, 0.02	-0.01	0.07	-0.03, 0.001	-0.04*	-0.02
Eosinophil % (%)	0.2	0.02*	0.05, 0.4	-0.04	0.7	-0.2, 0.2	-0.5*	-0.3
Monocytes (x10³/µl)	0.02	0.02*†	0.003, 0.03	0.02	0.005*	0.007, 0.04	-0.03*†	-0.02
Monocyte % (%)	0.7	<0.0001***	0.5, 0.9	0.6	<0.0001***	0.4, 0.8	-0.08	0.1
Basophils (x10³/µl)	0.0007	0.7	-0.003, 0.004	-0.0004	0.8	-0.004, 0.003	-9.7e-4	-0.0006
Basophil % (%)	0.01	0.5	-0.02, 0.05	-0.01	0.4	-0.05, 0.02	-0.02	0.006
Neutrophils (x10³/µl)	-0.4	<0.0001***	-0.5, -0.2	-0.3	<0.0001***	-0.4, -0.2	-0.3*†	-0.3*
Neutrophil % (%)	-2.5	<0.0001***	-3.5, -1.6	-2.1	<0.0001***	-3.05, -1.2	-0.5	-0.9
RBC (M/mL)	0.004	0.8	-0.02, 0.03	0.07	<0.0001***	0.04, 0.09	-0.02	-0.08
Hemoglobin (g/dL)	-0.2	<0.0001***	-0.3, -0.1	-0.02	0.6	-0.1, 0.06	0.05	-0.1
Hematocrit (%)	-0.4	0.0003**	-0.7, -0.2	0.01	0.9	-0.2, 0.2	0.1	-0.3
MCH (pg)	-0.5	<0.0001***	-0.6, -0.4	-0.4	<0.0001***	-0.5, -0.4	0.2	0.2
MCHC (g/dL)	-0.2	0.0001***	-0.2, -0.08	-0.07	0.08	-0.2, 0.008	0.02	-0.05
MCV (fl)	-1.0	<0.0001***	-1.2, -0.8	-1.2	<0.0001***	-1.3, -1.0	0.5	0.8
RDW CV (%)	-0.08	0.05*†	-0.2, -4e-5	-0.1	0.004*†	-0.2, -0.04	-0.2	-0.1
RDW SD (fl)	-0.6	<0.0001***	-0.8, -0.3	-0.8	<0.0001***	-1.0, -0.5	-0.2	0.04
Platelets (K/µL)	-9.8	<0.0001***	-13.4, -6.3	-3.06	0.09	-6.6, 0.4	8.4	1.3
PDW (%)	0.004	1.0	-0.3, 0.3	0.02	0.9	-0.2, 0.3	0.3	0.3
MPV (µm)	-0.07	0.4	-0.2, 0.09	-0.04	0.7	-0.2, 0.1	0.2	0.2
P-LCR (%)	-0.9	0.006*†	-1.6, -0.3	-1.2	0.0003**†	-1.9, -0.6	0.3	0.7

P-value: * ≤ 0.05, ** ≤ 0.001, *** ≤ 0.0001. Analyses adjusted for age, sex, BMI and medication use.

† = not significant after Tukey's correction

Abbreviations: *WBC = White Blood Cells, RBC = Red Blood Cells, MCH = Mean Corpuscular Hemoglobin, MCHC = Mean Corpuscular Hemoglobin Concentration, RDW CV = Red Cell Distribution Width Coefficient Of Variation, Red Cell Distribution Width Standard Deviation = RDW SD, PDW = Platelet Distribution Width, MPV = Mean Platelet Volume, P-LCR = Platelet-Large Cell Ratio*

Table 4. Within-group changes in anthropometric and blood pressure traits from T1 to T2 and between-group differences within T1 and T2.

Measured traits	PR group			NR group			Between-group estimate (T1)	Between-group estimate (T2)
	Within-group Estimate	P-value	95% CI	Within-group Estimate	P-value	95% CI		
Weight (kg)	-0.2	0.5	-0.7, 0.4	1.0	0.0002**†	0.5, 1.5	2.1	1.04
BMI (kg/m²)	-0.02	0.5¥	-0.07, 0.04	0.05	0.07	-0.004, 0.002	0.2*†	0.1
SBP (mmHg)	-1.9	0.06	-3.9, 0.09	-2.2	0.03*†	-4.2, -0.2	0.4	-0.8
DBP (mmHg)	-2.5	0.0002**	-3.7, -1.2	-2.2	0.0006**	-3.5, -1.0	0.02	-1.04

P-value**: * ≤ 0.05, ** ≤ 0.001, *** ≤ 0.0001
† = not significant after Tukey's correction
¥ = statistically significant after Tukey's correction (β= -9.6e-16, p < 0.0001)
Abbreviations: *BMI = Body Mass Index; SBP = Systolic Blood Pressure; DBP = Diastolic Blood Pressure*

Abbreviations

PR = Periodically restricted, NR = Non-restricted, T1 = Timepoint 1, T2 = Timepoint 2, BMI = Body Mass Index, SBP = Systolic Blood Pressure, DBP = Diastolic Blood Pressure, LDL = Low-Density Lipoprotein, HDL = High-Density Lipoprotein, Hba1c = Hemoglobin A1c, AST = Aspartate Aminotransferase, ALT = Alanine Aminotransferase, γ-GT = Glutamyltransferase, ALP = Alkaline Phosphatase, TSH = Thyroid-Stimulating Hormone, CRP = C-Reactive Protein, HOMA = Homeostasis Model Assessment, HOMA-B =HOMA-Beta-Cell Function, HOMA-IR = HOMA-Insulin Resistance, WBC = White Blood Cells, RBC = Red Blood Cells, MCH = Mean Corpuscular Hemoglobin, MCHC = Mean Corpuscular Hemoglobin Concentration, RDW CV = Red Cell Distribution Width Coefficient of Variation, Red Cell Distribution Width Standard Deviation = RDW SD, PDW = Platelet Distribution Width, MPV = Mean Platelet Volume, P-LCR = Platelet-Large Cell Ratio, SNP = single nucleotide polymorphism, MAF = Minor Allele Frequency, HWE = Hardy-Weinberg Equilibrium, CVD = Cardiovascular disease

Author contributions

EML: Conceptualization, Methodology, Formal analysis, Writing – original draft. AS: Formal analysis, Writing – Review & Editing. PB: Formal analysis, Writing – Review & Editing. SG: Data acquisition, Material Preparation, Writing – Review & Editing. AD: Data acquisition, Material Preparation, Writing – Review & Editing. MA: Data acquisition, Material Preparation, Writing – Review & Editing. PR: Interpretation, Writing – Review & Editing. IK: Conceptualization, Methodology, Interpretation, Writing – Review & Editing. ND: Conceptualization, Methodology, Interpretation, Writing – Review & Editing. NS: Conceptualization, Methodology, Interpretation, Writing – Review & Editing. MY: Interpretation, Writing – Review & Editing. KR: Data acquisition, Material Preparation, Writing

– Review & Editing. ASD: Supervision, Funding acquisition, Conceptualization, Methodology, Data acquisition, Material Preparation, Writing – original draft.

Acknowledgements

The authors would like to thank the FastBio study participants and the Interbalkan Hospital staff. We would also like to thank Dr Dimitrios Rouskas and Dr Loukas Kipouros for their invaluable help.

Funding

The FastBio study was supported through a European Research Council Grant to Antigone Dimas (FastBio – 716998).

Data availability

The data underlying this article will be shared on reasonable request to the corresponding author.

DISCLOSURES

Conflict of interest

None declared.

REFERENCES

1. Jiang, Y., K. Jarr, C. Layton, C.D. Gardner, J.F. Ashouri, M.T. Abreu, et al., *Therapeutic Implications of Diet in Inflammatory Bowel Disease and Related Immune-Mediated Inflammatory Diseases.* Nutrients, 2021. **13**(3).
2. Zhang, S., A. Stubbendorff, K. Olsson, U. Ericson, K. Niu, L. Qi, et al., *Adherence to the EAT-Lancet diet, genetic susceptibility, and risk of type 2 diabetes in Swedish adults.* Metabolism, 2023. **141**: p. 155401.
3. Dinu, M., R. Abbate, G.F. Gensini, A. Casini, and F. Sofi, *Vegetarian, vegan diets and multiple health outcomes: A systematic review with meta-analysis of observational studies.* Crit Rev Food Sci Nutr, 2017. **57**(17): p. 3640-3649.
4. Medawar, E., S. Huhn, A. Villringer, and A. Veronica Witte, *The effects of plant-based diets on the body and the brain: a systematic review.* Transl Psychiatry, 2019. **9**(1): p. 226.
5. Tong, T.Y.N., A. Perez-Cornago, K.E. Bradbury, and T.J. Key, *Biomarker Concentrations in White and British Indian Vegetarians and Nonvegetarians in the UK Biobank.* J Nutr, 2021. **151**(10): p. 3168-3179.
6. Termannsen, A.D., K.K.B. Clemmensen, J.M. Thomsen, O. Norgaard, L.J. Diaz, S.S. Torekov, et al., *Effects of vegan diets on cardiometabolic health: A systematic review and meta-analysis of randomized controlled trials.* Obes Rev, 2022. **23**(9): p. e13462.
7. Rees, K., L. Al-Khudairy, A. Takeda, and S. Stranges, *Vegan dietary pattern for the primary and secondary prevention of cardiovascular diseases.* Cochrane Database Syst Rev, 2021. **2**(2): p. Cd013501.
8. Yokoyama, Y., S.M. Levin, and N.D. Barnard, *Association between plant-based diets and plasma lipids: a systematic review and meta-analysis.* Nutr Rev, 2017. **75**(9): p. 683-698.

9. Selinger, E., M. Neuenschwander, A. Koller, J. Gojda, T. Kühn, L. Schwingshackl, et al., *Evidence of a vegan diet for health benefits and risks – an umbrella review of meta-analyses of observational and clinical studies.* Critical Reviews in Food Science and Nutrition, 2022: p. 1-11.

10. Key, T.J., K. Papier, and T.Y.N. Tong, *Plant-based diets and long-term health: findings from the EPIC-Oxford study.* Proc Nutr Soc, 2022. **81**(2): p. 190-198.

11. Tong, T.Y.N., P.N. Appleby, M.E.G. Armstrong, G.K. Fensom, A. Knuppel, K. Papier, et al., *Vegetarian and vegan diets and risks of total and site-specific fractures: results from the prospective EPIC-Oxford study.* BMC Med, 2020. **18**(1): p. 353.

12. Lederer, A.K., A. Maul-Pavicic, L. Hannibal, M. Hettich, C. Steinborn, C. Gründemann, et al., *Vegan diet reduces neutrophils, monocytes and platelets related to branched-chain amino acids - A randomized, controlled trial.* Clin Nutr, 2020. **39**(11): p. 3241-3250.

13. Link, V.M., P. Subramanian, F. Cheung, K.L. Han, A. Stacy, L. Chi, et al., *Differential peripheral immune signatures elicited by vegan versus ketogenic diets in humans.* Nat Med, 2024. **30**(2): p. 560-572.

14. Kjeldsen-Kragh, J., M. Haugen, C.F. Borchgrevink, E. Laerum, M. Eek, P. Mowinkel, et al., *Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis.* Lancet, 1991. **338**(8772): p. 899-902.

15. Derbyshire, E.J., *Flexitarian Diets and Health: A Review of the Evidence-Based Literature.* Front Nutr, 2016. **3**: p. 55.

16. Visseren, F.L.J., F. Mach, Y.M. Smulders, D. Carballo, K.C. Koskinas, M. Back, et al., *2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC).* Rev Esp Cardiol (Engl Ed), 2022. **75**(5): p. 429.

17. Sarri, K.O., M.K. Linardakis, F.N. Bervanaki, N.E. Tzanakis, and A.G. Kafatos, *Greek Orthodox fasting rituals: a hidden characteristic of the Mediterranean diet of Crete.* Br J Nutr, 2004. **92**(2): p. 277-84.

18. Wyse, C., G. O'Malley, A.N. Coogan, S. McConkey, and D.J. Smith, *Seasonal and daytime variation in multiple immune parameters in humans: Evidence from 329,261 participants of the UK Biobank cohort.* iScience, 2021. **24**(4): p. 102255.

19. Marees, A.T., H. de Kluiver, S. Stringer, F. Vorspan, E. Curis, C. Marie-Claire, et al., *A tutorial on conducting genome-wide association studies: Quality control and statistical analysis.* Int J Methods Psychiatr Res, 2018. **27**(2): p. e1608.

20. Purcell, S., B. Neale, K. Todd-Brown, L. Thomas, M.A. Ferreira, D. Bender, et al., *PLINK: a tool set for whole-genome association and population-based linkage analyses.* Am J Hum Genet, 2007. **81**(3): p. 559-75.

21. Primatesta, P., E. Falaschetti, S. Gupta, M.G. Marmot, and N.R. Poulter, *Association between smoking and blood pressure: evidence from the health survey for England.* Hypertension, 2001. **37**(2): p. 187-93.

22. Song, C. and R.S. Rosenson, *Competing Genetic Traits and Their Influence on LDL Cholesterol Concentration in Familial Hypercholesterolemia.* JACC Case Rep, 2024. **29**(2): p. 102171.

23. Vanhoye, X., C. Bardel, A. Rimbert, P. Moulin, P.A. Rollat-Farnier, M. Muntaner, et al., *A new 165-SNP low-density lipoprotein cholesterol polygenic risk score based on next generation sequencing outperforms previously published scores in routine diagnostics of familial hypercholesterolemia.* Transl Res, 2023. **255**: p. 119-127.

24. Hartwig, F.P., N.M. Davies, G. Hemani, and G. Davey Smith, *Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique.* Int J Epidemiol, 2016. **45**(6): p. 1717-1726.

25. group, S.w. and E.S.C.C.r. collaboration, *SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe.* Eur Heart J, 2021. **42**(25): p. 2439-2454.

26. Kuo, T.R. and C.H. Chen, *Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives.* Biomark Res, 2017. **5**: p. 18.

27.   Georgakouli, K., F. Siamata, D. Draganidis, P. Tsimeas, K. Papanikolaou, A. Batrakoulis, et al., *The Effects of Greek Orthodox Christian Fasting during Holy Week on Body Composition and Cardiometabolic Parameters in Overweight Adults.* Diseases, 2022. **10**(4).

28.   Hamczyk, M.R., R.M. Nevado, A. Barettino, V. Fuster, and V. Andres, *Biological Versus Chronological Aging: JACC Focus Seminar.* J Am Coll Cardiol, 2020. **75**(8): p. 919-930.

29.   Global Cardiovascular Risk, C., C. Magnussen, F.M. Ojeda, D.P. Leong, J. Alegre-Diaz, P. Amouyel, et al., *Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.* N Engl J Med, 2023. **389**(14): p. 1273-1285.

30.   Kent, L., D. Morton, P. Rankin, E. Ward, R. Grant, J. Gobble, et al., *The effect of a low-fat, plant-based lifestyle intervention (CHIP) on serum HDL levels and the implications for metabolic syndrome status - a cohort study.* Nutr Metab (Lond), 2013. **10**(1): p. 58.

31.   Law, M.R., N.J. Wald, and A.R. Rudnicka, *Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.* BMJ, 2003. **326**(7404): p. 1423.

32.   Menzel, J., A. Jabakhanji, R. Biemann, K. Mai, K. Abraham, and C. Weikert, *Systematic review and meta-analysis of the associations of vegan and vegetarian diets with inflammatory biomarkers.* Sci Rep, 2020. **10**(1): p. 21736.

33.   Chen, Y., H. Zhong, Y. Zhao, X. Luo, and W. Gao, *Role of platelet biomarkers in inflammatory response.* Biomark Res, 2020. **8**: p. 28.

34.   Awan, Z. and J. Genest, *Inflammation modulation and cardiovascular disease prevention.* Eur J Prev Cardiol, 2015. **22**(6): p. 719-33.

35.   Ridker, P.M., *From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction?* Cardiovasc Res, 2021. **117**(11): p. e138-e140.

36.   Despres, J.P., M.C. Pouliot, S. Moorjani, A. Nadeau, A. Tremblay, P.J. Lupien, et al., *Loss of abdominal fat and metabolic response to exercise training in obese women.* Am J Physiol, 1991. **261**(2 Pt 1): p. E159-67.

37.   Straznicky, N.E., E.A. Lambert, M.T. Grima, N. Eikelis, P.J. Nestel, T. Dawood, et al., *The effects of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects.* Diabetes Obes Metab, 2012. **14**(2): p. 139-48.

38.   Sanyal, A.J., N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, N.M. Bass, et al., *Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.* N Engl J Med, 2010. **362**(18): p. 1675-85.

39.   Greenblatt, M.B., J.N. Tsai, and M.N. Wein, *Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.* Clin Chem, 2017. **63**(2): p. 464-474.

40.   Lee, H.S. and J.H. Lee, *Early elevation of high-sensitivity C-reactive protein as a predictor for cardiovascular disease incidence and all-cause mortality: a landmark analysis.* Sci Rep, 2023. **13**(1): p. 14118.

41.   Willett, W., J. Rockstrom, B. Loken, M. Springmann, T. Lang, S. Vermeulen, et al., *Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems.* Lancet, 2019. **393**(10170): p. 447-492.